Inspirion Receives FDA Approval for First and only Immediate Release Opioid Analgesic with Abuse-Deterrent Label Claims
Inspirion Delivery Sciences, LLC (Inspirion) has received U.S. Food and Drug Administration (FDA) approval for RoxyBond, an abuse-deterrent formulation of oxycodone that uses physical and chemical barriers to deter abuse, without the use of aversive agents or opioid antagonists. RoxyBond is the first immediate-release opioid analgesic approved with labeling describing its abuse-deterrent properties. “Inspirion is pleased to receive FDA approval for our abuse-deterrent product, which is intended to address the long standing unmet need for immediate release abuse-deterrent opioids.” said Stefan Aigner, MD, CFA, CEO of Inspirion. Read more here.